CogNano

Executive Summary

CogNano is a Japanese biotechnology company pioneering the discovery of novel biomarkers and drug candidates for difficult-to-treat cancers, including triple-negative breast cancer (TNBC) and pancreatic cancer. Leveraging its proprietary VHH antibody platform and AI-driven Inverse Biomarker Exploring Technology (IBMET), the company analyzes vast antibody-antigen datasets from in-house alpaca and shark colonies to identify previously unknown therapeutic targets with high precision. Founded in 2014 and headquartered in Kyoto, CogNano operates at the preclinical stage, focusing on oncology and infectious diseases. Its unique approach combines the high specificity of VHH antibodies with AI-powered target discovery, potentially unlocking new treatment avenues for patients with limited options. Despite being a private entity with no disclosed funding rounds, the technology's novelty and focus on unmet medical needs position it as a promising player in the biotech landscape. The company's success hinges on advancing its lead candidates into formal preclinical studies and securing partnerships or funding to support development.

Upcoming Catalysts (preview)

• Q4 2026Presentation of preclinical proof-of-concept data for lead VHH antibody candidates in TNBC or pancreatic cancer models70% success
• Q2 2027Announcement of a strategic research collaboration or licensing agreement with a pharmaceutical company50% success
• Q3 2027Series A financing round to advance pipeline toward IND-enabling studies60% success